Pharming Group announces the filing of its 2024 Annual Report and Form 20-F
Pharming Group (Euronext Amsterdam: PHARM / Nasdaq: PHAR) has announced the filing of its Annual Report for the year ended December 31, 2024. The company has made the report accessible to investors through their website Pharming.com under the Investors/Financial documents section. Additionally, Pharming has filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC), which will be available on both the company's website under Investors/SEC filings and the SEC website.
Pharming Group (Euronext Amsterdam: PHARM / Nasdaq: PHAR) ha annunciato il deposito del suo Rapporto Annuale per l'anno conclusosi il 31 dicembre 2024. L'azienda ha reso il rapporto accessibile agli investitori tramite il proprio sito web Pharming.com nella sezione Investitori/Documenti finanziari. Inoltre, Pharming ha presentato il suo Rapporto Annuale sul Modulo 20-F alla Securities and Exchange Commission (SEC) degli Stati Uniti, che sarà disponibile sia sul sito dell'azienda nella sezione Investitori/Depositi SEC che sul sito della SEC.
Pharming Group (Euronext Ámsterdam: PHARM / Nasdaq: PHAR) ha anunciado la presentación de su Informe Anual para el año que finalizó el 31 de diciembre de 2024. La empresa ha hecho accesible el informe a los inversores a través de su sitio web Pharming.com en la sección Inversores/Documentos financieros. Además, Pharming ha presentado su Informe Anual en el Formulario 20-F a la Comisión de Valores y Bolsa de EE. UU. (SEC), que estará disponible tanto en el sitio web de la empresa en la sección Inversores/Presentaciones a la SEC como en el sitio web de la SEC.
Pharming Group (Euronext 암스테르담: PHARM / 나스닥: PHAR)는 2024년 12월 31일 종료된 연간 보고서의 제출을 발표했습니다. 회사는 투자자들이 Pharming.com 웹사이트의 투자자/재무 문서 섹션을 통해 보고서에 접근할 수 있도록 했습니다. 또한, Pharming은 미국 증권 거래 위원회(SEC)에 20-F 양식의 연간 보고서를 제출했으며, 이는 회사 웹사이트의 투자자/SEC 제출 섹션과 SEC 웹사이트에서 모두 이용할 수 있습니다.
Pharming Group (Euronext Amsterdam: PHARM / Nasdaq: PHAR) a annoncé le dépôt de son Rapport Annuel pour l'année se terminant le 31 décembre 2024. L'entreprise a rendu le rapport accessible aux investisseurs via son site web Pharming.com dans la section Investisseurs/Documents financiers. De plus, Pharming a déposé son Rapport Annuel sur le Formulaire 20-F auprès de la Securities and Exchange Commission (SEC) des États-Unis, qui sera disponible à la fois sur le site de l'entreprise dans la section Investisseurs/Dépôts SEC et sur le site de la SEC.
Pharming Group (Euronext Amsterdam: PHARM / Nasdaq: PHAR) hat die Einreichung seines Jahresberichts für das am 31. Dezember 2024 endende Jahr bekannt gegeben. Das Unternehmen hat den Bericht für Investoren über die Website Pharming.com im Bereich Investoren/Finanzdokumente zugänglich gemacht. Darüber hinaus hat Pharming seinen Jahresbericht im Formular 20-F bei der US-amerikanischen Securities and Exchange Commission (SEC) eingereicht, der sowohl auf der Unternehmenswebsite im Bereich Investoren/SEC-Einreichungen als auch auf der SEC-Website verfügbar sein wird.
- None.
- None.
Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2024 (the “Period”). The Annual Report is available under Investors/Financial documents on the Pharming.com website.
The Company also announces the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the Period. The 2024 Annual Report on Form 20-F can be found under Investors/SEC filings on Pharming.com and through the SEC website once it has been filed.
About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
Inside Information
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
FTI Consulting, London, UK
Simon Conway/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Attachment
FAQ
Where can investors access Pharming Group's 2024 Annual Report?
When did Pharming Group (PHARM) file its 2024 Annual Report?
How can investors find Pharming's Form 20-F filing for 2024?
What stock exchanges is Pharming Group (PHARM) listed on?
